NTRK1 and neoplasm: Sorafenib inhibits hepatoma cell proliferation, metastasis, and tumor neovascularization mainly by inhibiting Raf-1 and a variety of tyrosine kinase receptors, including VEGFR-1/-2/-3, PDGFR-β, c-Kit, FLT-3, and RET.